Ambalal Sarabhai

how big is Ambalal Sarabhai?

As of Jun 06, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 284.00 Cr, with recent net sales of 196.18 Cr and a net profit of 4.93 Cr. Shareholder's funds are 137.13 Cr, and total assets amount to 250.23 Cr.

Market Cap: As of Jun 06, Ambalal Sarabhai Enterprises Ltd has a market capitalization of 284.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 196.18 Cr and a sum of Net Profit of 4.93 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 137.13 Cr, while Total Assets amount to 250.23 Cr.

What does Ambalal Sarabhai do?

Ambalal Sarabhai Enterprises Ltd is a micro-cap Indian company in the Pharmaceuticals & Biotechnology sector, focusing on manufacturing and marketing pharmaceutical and diagnostic products. As of March 2025, it reported net sales of 65 Cr and a market cap of Rs 279 Cr.

Overview: <BR>Ambalal Sarabhai Enterprises Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, engaged in the manufacturing and marketing of pharmaceutical, molecular diagnostics, and electronics products.<BR><BR>History: <BR>Incorporated on June 5, 1978, Ambalal Sarabhai Enterprises Ltd is one of the oldest pharmaceutical healthcare companies in India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 65 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 279 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 8.52% <BR>Price to Book: 2.02 <BR><BR>Contact Details: <BR>Address: Shanti Sadan, Mirzapur Road Ahmedabad Gujarat : 380001 <BR>Tel: 91-79-25507671/25507073 <BR>Email: ketanadhvaryu@sarabhai.co.in <BR>Website: http://www.ase.life

Who are in the management team of Ambalal Sarabhai?

As of March 2022, the management team of Ambalal Sarabhai includes Kartikeya V Sarabhai (Chairman & Wholetime Director), Anil H Parekh (Non Executive Director), Chaula Shastri (Whole-time Director), and several independent directors, among others, overseeing the company's strategic direction and governance.

As of March 2022, the management team of Ambalal Sarabhai includes the following individuals:<BR><BR>1. **Kartikeya V Sarabhai** - Chairman & Wholetime Director<BR>2. **Anil H Parekh** - Non Executive Director<BR>3. **Ashwin P Hathi** - Independent Director<BR>4. **Chaula Shastri** - Whole-time Director<BR>5. **Chandrashekhar B. Bohra** - Independent Director<BR>6. **Damodar Sejpal** - Company Secretary & Compliance Officer<BR>7. **Mayur K Swedia** - Independent Director<BR>8. **Brijesh Khandelwal** - Director and Additional Director<BR><BR>This team is responsible for the strategic direction and governance of the company.

Has Ambalal Sarabhai declared dividend?

No Dividend History Available

Who are the peers of the Ambalal Sarabhai?

Ambalal Sarabhai's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs, Kimia Bioscien, and Sat Kartar. While Sun Pharma and others show excellent management and growth, Ambalal Sarabhai has below-average performance, with a 1-year return of -21.20%.

Peers: The peers of Ambalal Sarabhai are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Coral Labs., Kimia Bioscien., Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Below Average management risk is found at Ambalal Sarabhai, Natural Capsules, Coral Labs., Kimia Bioscien., and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Ambalal Sarabhai and Kimia Bioscien., with the rest showing Good or Below Average growth. Excellent capital structure is seen in Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Coral Labs., while Good capital structure is noted for Ambalal Sarabhai, Natural Capsules, and Sat Kartar, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Ambalal Sarabhai has the lowest at -21.20%. Compared to its peers, Ambalal Sarabhai's return is significantly lower. Additionally, the six-month return is negative for Ambalal Sarabhai, Natural Capsules, Coral Labs., and Kimia Bioscien.

Is Ambalal Sarabhai overvalued or undervalued?

As of June 2, 2025, Ambalal Sarabhai is considered an attractive investment due to its undervalued status, with a PE ratio of 23.05, a PEG ratio of 0.28 indicating strong growth potential, and a competitive ROE of 8.52%, despite recent underperformance against the Sensex.

As of 2 June 2025, the valuation grade for Ambalal Sarabhai has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently assessed as undervalued, particularly given its price-to-earnings (PE) ratio of 23.05, a price-to-book value of 1.96, and an EV to EBITDA ratio of 38.95. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.<BR><BR>In comparison to its peers, Ambalal Sarabhai's PE ratio aligns closely with the industry average, while its PEG ratio of 0.28 indicates strong growth potential relative to its price. Notably, its return on equity (ROE) stands at 8.52%, which is competitive within the pharmaceuticals and biotechnology sector. Despite recent underperformance against the Sensex, particularly in the year-to-date and one-year periods, the overall valuation metrics suggest that Ambalal Sarabhai presents a compelling investment opportunity at its current price of 36.70.

What is the technical trend for Ambalal Sarabhai?

As of June 4, 2025, Ambalal Sarabhai's technical trend has shifted to bearish, driven by daily moving averages and Bollinger Bands indicating bearish conditions, despite mixed signals from the MACD and KST across different time frames.

As of 4 June 2025, the technical trend for Ambalal Sarabhai has changed from mildly bearish to bearish. The current stance is bearish with moderate strength, primarily driven by the daily moving averages indicating a bearish trend and both weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly but mildly bearish monthly. Overall, the indicators reflect a bearish sentiment, particularly in the short-term daily analysis.

Who are the top shareholders of the Ambalal Sarabhai?

The top shareholders of Ambalal Sarabhai are Sarabhai Holdings Private Limited with 25.76%, individual investors with 57.42%, and Haryana Containers Limited as the largest public shareholder at 1.61%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Ambalal Sarabhai include Sarabhai Holdings Private Limited, which holds the highest stake at 25.76%. Individual investors collectively own 57.42% of the company. Additionally, Haryana Containers Limited is the highest public shareholder with a holding of 1.61%. There are also two foreign institutional investors (FIIs) with a combined holding of 0.38%. Notably, there are no pledged promoter holdings and no mutual funds currently holding shares in the company.

How has been the historical performance of Ambalal Sarabhai?

Ambalal Sarabhai's historical performance shows fluctuating results, with net sales increasing from 170.28 crore in March 2023 to 196.19 crore in March 2025, but profitability declined significantly, with profit after tax falling from 12.14 crore to 4.29 crore and negative cash flow from operating activities. Total liabilities and assets both rose, indicating a stable asset base despite financial challenges.

Answer:<BR>The historical performance of Ambalal Sarabhai shows a fluctuating trend in key financial metrics over the years, with notable changes in revenue and profitability.<BR><BR>Breakdown:<BR>Ambalal Sarabhai's net sales increased from 170.28 crore in March 2023 to 196.19 crore in March 2025, reflecting a growth trend. However, the total operating income showed a decline from 196.75 crore in March 2022 to 196.19 crore in March 2025. The company's total expenditure, excluding depreciation, rose from 161.71 crore in March 2023 to 188.10 crore in March 2025, impacting operating profit, which decreased from 21.06 crore in March 2023 to 19.47 crore in March 2025. Profit before tax also declined from 15.86 crore in March 2023 to 4.19 crore in March 2025, while profit after tax fell from 12.14 crore to 4.29 crore in the same period. The consolidated net profit showed a similar downward trend, decreasing from 11.45 crore in March 2023 to 4.93 crore in March 2025. On the balance sheet, total liabilities increased from 245.74 crore in March 2023 to 268.23 crore in March 2025, while total assets rose from 245.74 crore to 268.23 crore, indicating a stable asset base despite rising liabilities. Cash flow from operating activities turned negative, dropping from 5 crore in March 2023 to -17 crore in March 2025, which reflects challenges in cash generation. Overall, while revenue showed some growth, profitability and cash flow faced significant pressures during this period.

Are Ambalal Sarabhai Enterprises Ltd latest results good or bad?

Ambalal Sarabhai Enterprises Ltd's latest results show significant quarterly profit growth, but concerns arise from reliance on non-operating income and a decline in net profit over nine months. Overall, while there are positive signs, caution is advised for potential investors due to underlying financial health issues and poor stock performance.

Ambalal Sarabhai Enterprises Ltd's latest results present a mixed picture. On one hand, the company reported a consolidated net profit of ₹3.64 crore for Q3 FY26, marking a significant improvement of 750% quarter-on-quarter (QoQ) and a 63.23% increase year-on-year (YoY). Revenue also saw a positive trend, rising to ₹52.00 crore, which is a 16.99% increase QoQ and a 13.12% increase YoY.<BR><BR>However, while these figures suggest a recovery from previous quarters, there are underlying concerns. A substantial portion of the operating profit was derived from non-operating income, which accounted for nearly 39% of the operating profit in this quarter. This raises questions about the sustainability and quality of the earnings. Additionally, the nine-month performance shows a decline in net profit by 22.38% compared to the previous six-month period, indicating that the overall trend may not be as positive as the quarterly results suggest.<BR><BR>Moreover, the company's stock has significantly underperformed the pharmaceuticals sector, declining 48.30% over the past year compared to the sector's gain of 6.53%. The stock is trading below key moving averages and is just above its 52-week low, which reflects bearish sentiment among investors.<BR><BR>In summary, while the latest quarterly results show some positive growth, the overall financial health and sustainability of Ambalal Sarabhai Enterprises Ltd raise concerns, suggesting that caution is warranted for potential investors.

When is the next results date for Ambalal Sarabhai Enterprises Ltd?

The next results date for Ambalal Sarabhai Enterprises Ltd is 21 May 2026.

The next results date for Ambalal Sarabhai Enterprises Ltd is scheduled for 21 May 2026.

Why is Ambalal Sarabhai Enterprises Ltd falling/rising?

As of 20-May, Ambalal Sarabhai Enterprises Ltd's stock price has risen to 32.75, reflecting a 4.57% increase, driven by strong performance against its sector and consistent gains over the past two days. The stock is trading above key moving averages, indicating a robust upward trend despite a decline in investor participation.

As of 20-May, Ambalal Sarabhai Enterprises Ltd is experiencing a rise in its stock price, currently at 32.75, reflecting an increase of 1.43 or 4.57%. This upward movement can be attributed to several factors. The stock has outperformed the sector by 4.92% today and has shown consecutive gains over the last two days, accumulating a total return of 5.09% during this period. Additionally, the stock opened with a gain of 2.11% today and reached an intraday high of Rs 33.38, marking a 6.58% increase.<BR><BR>Moreover, Ambalal Sarabhai is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Despite a decrease in investor participation, with delivery volume falling by 27.38% against the 5-day average, the stock remains liquid enough for trading. Overall, these factors contribute to the positive momentum in the stock price of Ambalal Sarabhai Enterprises Ltd.

Which are the latest news on Ambalal Sarabhai?

Should I buy, sell or hold Ambalal Sarabhai Enterprises Ltd?